Utility of C-terminal telopeptide in evaluating levothyroxine replacement therapy-induced bone loss

Alap L. Christy, Vivian D'Souza, Ruby P. Babu, Sohil Takodara, Poornima Manjrekar, Anupama Hegde, M. S. Rukmini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Levothyroxine (LT4) therapy has shown to have effects on bone metabolism though its deleterious effect on bone remodeling is debat-able. This study was aimed at assessing the diagnostic utility of the bone remodeling marker C-terminal telopeptide (CTx) in detecting early bone loss. Materials and methods: In this case-control study, 84 premenopausal women of 30-45 years of age were selected. Out of them, 28 were recently diagnosed of hypothyroidism (not on LT4), 28 were on LT4 replacement therapy (100-200 μg/day) for more than five years, and 28 had euthyroid. Plasma CTx levels were estimated. Bone mineral density (BMD) was measured by quantitative ultrasound (QUS) method. Pearson's coefficient of correla-tion and ANOVA were used for statistical analysis. Results: CTx was most elevated in LT4-treated group (0.497 ± 0.209 ng/mL). It showed a significant negative correlation with T-score and Z-score of BMD values. In the treatment group of more than 150 μg/day, CTx showed significantly negative correlation with TSH (r = -0.462, P = 0.047). Conclusion: LT4 therapy induces bone loss in hypothyroid patients. CTx levels can measure such bone loss along with BMD. Regular monitoring of CTx with adjustment in LT4 doses may help delay osteoporosis induced by prolonged LT4 replacement therapy.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalBiomarker Insights
Volume9
DOIs
Publication statusPublished - 03-03-2014

Fingerprint

Thyroxine
Bone
Bone and Bones
Bone Density
Bone Remodeling
Minerals
Therapeutics
Hypothyroidism
Osteoporosis
Case-Control Studies
Analysis of Variance
collagen type I trimeric cross-linked peptide
Analysis of variance (ANOVA)
Metabolism
Statistical methods
Ultrasonics
Plasmas
Monitoring

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Biochemistry, medical

Cite this

@article{ec2530004db7408eb5f4dcd93012fdc8,
title = "Utility of C-terminal telopeptide in evaluating levothyroxine replacement therapy-induced bone loss",
abstract = "Background: Levothyroxine (LT4) therapy has shown to have effects on bone metabolism though its deleterious effect on bone remodeling is debat-able. This study was aimed at assessing the diagnostic utility of the bone remodeling marker C-terminal telopeptide (CTx) in detecting early bone loss. Materials and methods: In this case-control study, 84 premenopausal women of 30-45 years of age were selected. Out of them, 28 were recently diagnosed of hypothyroidism (not on LT4), 28 were on LT4 replacement therapy (100-200 μg/day) for more than five years, and 28 had euthyroid. Plasma CTx levels were estimated. Bone mineral density (BMD) was measured by quantitative ultrasound (QUS) method. Pearson's coefficient of correla-tion and ANOVA were used for statistical analysis. Results: CTx was most elevated in LT4-treated group (0.497 ± 0.209 ng/mL). It showed a significant negative correlation with T-score and Z-score of BMD values. In the treatment group of more than 150 μg/day, CTx showed significantly negative correlation with TSH (r = -0.462, P = 0.047). Conclusion: LT4 therapy induces bone loss in hypothyroid patients. CTx levels can measure such bone loss along with BMD. Regular monitoring of CTx with adjustment in LT4 doses may help delay osteoporosis induced by prolonged LT4 replacement therapy.",
author = "Christy, {Alap L.} and Vivian D'Souza and Babu, {Ruby P.} and Sohil Takodara and Poornima Manjrekar and Anupama Hegde and Rukmini, {M. S.}",
year = "2014",
month = "3",
day = "3",
doi = "10.4137/BMI.S13965",
language = "English",
volume = "9",
pages = "1--6",
journal = "Biomarker Insights",
issn = "1177-2719",
publisher = "Libertas Academica Ltd.",

}

Utility of C-terminal telopeptide in evaluating levothyroxine replacement therapy-induced bone loss. / Christy, Alap L.; D'Souza, Vivian; Babu, Ruby P.; Takodara, Sohil; Manjrekar, Poornima; Hegde, Anupama; Rukmini, M. S.

In: Biomarker Insights, Vol. 9, 03.03.2014, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Utility of C-terminal telopeptide in evaluating levothyroxine replacement therapy-induced bone loss

AU - Christy, Alap L.

AU - D'Souza, Vivian

AU - Babu, Ruby P.

AU - Takodara, Sohil

AU - Manjrekar, Poornima

AU - Hegde, Anupama

AU - Rukmini, M. S.

PY - 2014/3/3

Y1 - 2014/3/3

N2 - Background: Levothyroxine (LT4) therapy has shown to have effects on bone metabolism though its deleterious effect on bone remodeling is debat-able. This study was aimed at assessing the diagnostic utility of the bone remodeling marker C-terminal telopeptide (CTx) in detecting early bone loss. Materials and methods: In this case-control study, 84 premenopausal women of 30-45 years of age were selected. Out of them, 28 were recently diagnosed of hypothyroidism (not on LT4), 28 were on LT4 replacement therapy (100-200 μg/day) for more than five years, and 28 had euthyroid. Plasma CTx levels were estimated. Bone mineral density (BMD) was measured by quantitative ultrasound (QUS) method. Pearson's coefficient of correla-tion and ANOVA were used for statistical analysis. Results: CTx was most elevated in LT4-treated group (0.497 ± 0.209 ng/mL). It showed a significant negative correlation with T-score and Z-score of BMD values. In the treatment group of more than 150 μg/day, CTx showed significantly negative correlation with TSH (r = -0.462, P = 0.047). Conclusion: LT4 therapy induces bone loss in hypothyroid patients. CTx levels can measure such bone loss along with BMD. Regular monitoring of CTx with adjustment in LT4 doses may help delay osteoporosis induced by prolonged LT4 replacement therapy.

AB - Background: Levothyroxine (LT4) therapy has shown to have effects on bone metabolism though its deleterious effect on bone remodeling is debat-able. This study was aimed at assessing the diagnostic utility of the bone remodeling marker C-terminal telopeptide (CTx) in detecting early bone loss. Materials and methods: In this case-control study, 84 premenopausal women of 30-45 years of age were selected. Out of them, 28 were recently diagnosed of hypothyroidism (not on LT4), 28 were on LT4 replacement therapy (100-200 μg/day) for more than five years, and 28 had euthyroid. Plasma CTx levels were estimated. Bone mineral density (BMD) was measured by quantitative ultrasound (QUS) method. Pearson's coefficient of correla-tion and ANOVA were used for statistical analysis. Results: CTx was most elevated in LT4-treated group (0.497 ± 0.209 ng/mL). It showed a significant negative correlation with T-score and Z-score of BMD values. In the treatment group of more than 150 μg/day, CTx showed significantly negative correlation with TSH (r = -0.462, P = 0.047). Conclusion: LT4 therapy induces bone loss in hypothyroid patients. CTx levels can measure such bone loss along with BMD. Regular monitoring of CTx with adjustment in LT4 doses may help delay osteoporosis induced by prolonged LT4 replacement therapy.

UR - http://www.scopus.com/inward/record.url?scp=84896858537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896858537&partnerID=8YFLogxK

U2 - 10.4137/BMI.S13965

DO - 10.4137/BMI.S13965

M3 - Article

AN - SCOPUS:84896858537

VL - 9

SP - 1

EP - 6

JO - Biomarker Insights

JF - Biomarker Insights

SN - 1177-2719

ER -